Co-founded by faculty from Columbia University and University of Melbourne, Praxis Precision Medicines targets CNS disorders.

Praxis Precision Medicines, a US-based gene therapy developer focusing central nervous system disorders, collected $110m in series C1 funding yesterday from investors including pharmaceutical firm Novo Holdings.
Eventide Asset Management led the round, which also included Vida Ventures, Blackstone Life Sciences, OCV Partners, Avoro Capital Advisors, Surveyor Capital, Point72, Cormorant Asset Management, Qatar Investment Authority, Irving Investors, Adage Capital Management, Verition Fund Management and Ample Plus Fund.
Founded in 2015, Praxis Precision Medicines is developing gene therapies for…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in